HOLX Stock Overview
Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
HOLX passed our risk checks.
Hologic, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$73.50 |
52 Week High | US$77.00 |
52 Week Low | US$60.90 |
Beta | 0.98 |
11 Month Change | 0.68% |
3 Month Change | 3.52% |
1 Year Change | 12.39% |
33 Year Change | 21.33% |
5 Year Change | 63.33% |
Change since IPO | 91.34% |
Recent News & Updates
Recent updates
Shareholder Returns
HOLX | AT Medical Equipment | AT Market | |
---|---|---|---|
7D | 0.7% | 0.4% | 0.3% |
1Y | 12.4% | 22.9% | 5.6% |
Return vs Industry: HOLX underperformed the Austrian Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: HOLX exceeded the Austrian Market which returned 5.6% over the past year.
Price Volatility
HOLX volatility | |
---|---|
HOLX Average Weekly Movement | 2.3% |
Medical Equipment Industry Average Movement | 5.6% |
Market Average Movement | 3.5% |
10% most volatile stocks in AT Market | 6.1% |
10% least volatile stocks in AT Market | 1.9% |
Stable Share Price: HOLX has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: HOLX's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1985 | 6,990 | Steve MacMillan | www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
HOLX fundamental statistics | |
---|---|
Market cap | €16.98b |
Earnings (TTM) | €641.52m |
Revenue (TTM) | €3.65b |
26.4x
P/E Ratio4.6x
P/S RatioIs HOLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HOLX income statement (TTM) | |
---|---|
Revenue | US$3.99b |
Cost of Revenue | US$1.57b |
Gross Profit | US$2.42b |
Other Expenses | US$1.71b |
Earnings | US$701.50m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
Nov 04, 2024
Earnings per share (EPS) | 3.02 |
Gross Margin | 60.58% |
Net Profit Margin | 17.59% |
Debt/Equity Ratio | 51.4% |
How did HOLX perform over the long term?
See historical performance and comparison